Cargando…
Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions
Multiple myeloma is a malignancy of B-cells that is characterized by the clonal expansion and accumulation of malignant plasma cells in the bone marrow. This disease remains incurable, and a median survival of 3-5 years has been reported with the use of current treatments. Viral-based therapies offe...
Autores principales: | Raus, Svjetlana, Coin, Silvia, Monsurrò, Vladia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259514/ https://www.ncbi.nlm.nih.gov/pubmed/22259628 http://dx.doi.org/10.5045/kjh.2011.46.4.229 |
Ejemplares similares
-
Freedom to choose a cure: how safe is a deadly cancer?
por: Monsurró, Vladia
Publicado: (2010) -
Microarray Analysis for a Comprehensive Immunological-Status Evaluation during Cancer Vaccine Immune Monitoring
por: Monsurrò, Vladia, et al.
Publicado: (2011) -
Next generation sequencing: new tools in immunology and hematology
por: Mori, Antonio, et al.
Publicado: (2013) -
Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma
por: Amundarain, Ane, et al.
Publicado: (2022) -
New therapies in multiple myeloma
por: Merchionne, F., et al.
Publicado: (2007)